The so-called pharmaceutical intermediates are intermediate chemicals produced in the process of chemical drug synthesis, which can often be synthesized into raw materials and finally made into finished drugs with a difference of one to two steps. Basic chemical raw materials are the upstream of pharmaceutical intermediates, while raw materials and preparations are downstream of pharmaceutical intermediates. Basic chemical raw materials, pharmaceutical intermediates, raw materials and preparations constitute a complete industrial chain of the chemical pharmaceutical industry.

　　According to the data of "China Pharmaceutical Intermediates Industry Market Research and Investment Forecast Analysis Report" released by Qianzhan Industry Research Institute, from 2008 to 2014, the market size of my country's chemical raw material pharmaceutical industry increased year by year, reaching 424.035 billion yuan in 2014, a year-on-year increase of 11.01% ; Judging from the growth rate of the chemical raw material pharmaceutical industry, the growth rate in 2011 was 22.59%, the highest in recent years. Judging from these economic indicators, the chemical raw material pharmaceutical industry still maintains a fairly obvious growth trend. The prospect of the chemical raw material drug market is promising, which will surely promote the strengthening of upstream pharmaceutical intermediates.

　　my country's pharmaceutical intermediate industry started in the 1970s. After more than 30 years of rapid development, the production of pharmaceutical intermediates in my country can basically meet the needs of my country's pharmaceutical production. Only a small part needs to be imported, such as GCLE, which is urgently needed to be imported. High-end intermediates. From 2008 to 2014, the total output value of my country's pharmaceutical intermediate industry increased year by year. Specifically, in 2013, the total output value of my country's pharmaceutical intermediate industry was 349.070 billion yuan, a year-on-year increase of 13.89%; in 2014, the total output value of my country's pharmaceutical intermediate industry was 384.552 billion yuan, a year-on-year increase of 10.16%.

　　The oversupply of pharmaceutical intermediates in my country is more prominent, and the dependence on exports is gradually increasing. However, my country's exports are mainly concentrated in bulk products such as vitamin C, penicillin, acetaminophen, citric acid and its salts and esters. The values ​​are all on the low side, and their large-scale production has caused an oversupply situation in the domestic pharmaceutical intermediate market. High-tech products still mainly rely on imports.

　　For the protection of amino acid pharmaceutical intermediates, most of the products produced by domestic manufacturers are single in variety and unstable in quality, and they mainly produce customized products for foreign biopharmaceutical companies. Only some enterprises with strong research and development capabilities, advanced production facilities and large-scale production experience can obtain high profits in the competition.